Anticholinergic Drugs

Vardanyan, Ruben; Hruby, Victor J.

doi:10.1016/b978-0-12-411492-0.00014-6

Cited by 1 publication

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 In some circumstances, these anticholinergic actions have intended therapeutic effects, for example, the use of amitriptyline in the treatment of chronic pain, but in others, they are a side effect of a drug used primarily for other pharmacological actions, such as atenolol. 2 [1][2][3] resulting in a high overall prevalence of these medications. Anticholinergic drugs have many adverse effects that include dry mouth, constipation, increased heart rate, confusion, and increased risk of falls.…”

Section: Introductionmentioning

confidence: 99%

Barriers and facilitators to reducing anticholinergic burden from the perspectives of patients, their carers, and healthcare professionals: A protocol for qualitative evidence synthesis

Stewart

Gallacher

Nakham

et al. 2019

J Evidence Based Medicine

View full text Add to dashboard Cite

Anticholinergic drugs are prescribed for a range of conditions including gastrointestinal disorders, overactive bladder, allergies, and depression. While in some circumstances anticholinergic effects are therapeutic, they also pose many undesired or adverse effects. The overall impact from concomitant use of multiple medications with anticholinergic properties is termed anticholinergic burden (ACB). Greater ACB is associated with increased risks of impaired physical and cognitive function, falls, cardiovascular events, and mortality. This has led to the development of interventions aimed at reducing ACB through the deprescribing of anticholinergic drugs. However, little is known about the implementation issues that may influence successful embedding and integration of such interventions into routine clinical practice. In this paper, we present the protocol for our systematic review that aims to identify the qualitative evidence for the barriers and facilitators to reduce ACB from the perspectives of patients, carers, and healthcare professionals. A comprehensive search strategy will be conducted across OVID Medline, EMBASE, PsycInfo, and CINAHL. The review will be conducted in accordance with ENTREQ (Enhancing Transparency in Reporting the Synthesis of Qualitative Research) and has been registered with PROSPERO (Registration CRD42018109084). Normalization process theory (NPT) will be used to explore, understand, and explain qualitative data in relation to factors that act as barriers or facilitators to ACB reduction.

show abstract

Section: Introductionmentioning

confidence: 99%